Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 153 articles:
HTML format
Text format



Single Articles


    November 2018
  1. MEI M, Aldoss I, Marcucci G, Pullarkat V, et al
    Hypomethylating Agents in combination with Venetoclax for Acute Myeloid Leukemia: Update on Clinical trial data and Practical Considerations for use.
    Am J Hematol. 2018 Nov 30. doi: 10.1002/ajh.25369.
    PubMed     Text format     Abstract available


  2. POIRE X, Labopin M, Polge E, Blaise D, et al
    Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission.
    Am J Hematol. 2018 Nov 19. doi: 10.1002/ajh.25355.
    PubMed     Text format     Abstract available


  3. ANDREANI G, Dragani M, Serra A, Nicoli P, et al
    Venetoclax plus Decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
    Am J Hematol. 2018 Nov 15. doi: 10.1002/ajh.25352.
    PubMed     Text format    


  4. SHANMUGAM V, Dorfman DM
    Acute myeloid leukemia with minimal differentiation (AML M0) mimicking acute lymphoblastic leukemia.
    Am J Hematol. 2018 Nov 15. doi: 10.1002/ajh.25354.
    PubMed     Text format    


  5. SAINI N, Cerny J, Furtado V, Desmond A, et al
    Elderly do benefit from induction chemotherapy: High dose mitoxantrone based ("5+1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia.
    Am J Hematol. 2018 Nov 12. doi: 10.1002/ajh.25347.
    PubMed     Text format     Abstract available


  6. SHORT NJ, Jabbour E, Albitar M, de Lima M, et al
    Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts.
    Am J Hematol. 2018 Nov 5. doi: 10.1002/ajh.25338.
    PubMed     Text format     Abstract available


    October 2018
  7. BAHASHWAN S, Molucon-Chabrot C, Hermet E, Ravinet A, et al
    Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25332.
    PubMed     Text format    


  8. LITZOW MR, Wang XV, Carroll MP, Karp JE, et al
    A Randomized Trial of Three Novel Regimens for Recurrent Acute Myeloid Leukemia Demonstrates the Continuing Challenge of Treating this Difficult Disease.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25333.
    PubMed     Text format     Abstract available


  9. JELINEK T, Mihalyova J, Kascak M, Duras J, et al
    Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t[11;14].
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25331.
    PubMed     Text format    


  10. KONUMA T, Harada K, Yamasaki S, Mizuno S, et al
    Upfront allogeneic HCT vs remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: a propensity score matched analysis.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25336.
    PubMed     Text format     Abstract available


  11. LOEFF FC, Rijs K, van Egmond EHM, Zoutman WH, et al
    Loss of the GPI-anchor in B-lymphoblastic leukemia by epigenetic downregulation of PIGH expression.
    Am J Hematol. 2018 Oct 29. doi: 10.1002/ajh.25337.
    PubMed     Text format     Abstract available


  12. RENAUD L, Nibourel O, Marceau-Renaut A, Gruson B, et al
    Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: a study of the French Hauts-de-France AML observatory.
    Am J Hematol. 2018 Oct 25. doi: 10.1002/ajh.25328.
    PubMed     Text format    


  13. SHORT NJ, Jabbour E, Naqvi K, Patel A, et al
    A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.
    Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25318.
    PubMed     Text format     Abstract available


  14. HEHLMANN R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, et al
    Tyrosine Kinase Inhibitor Interruptions, Discontinuations and Switching in Patients with Chronic-Phase Chronic Myeloid Leukemia in Routine Clinical Practice: SIMPLICITY.
    Am J Hematol. 2018 Oct 5. doi: 10.1002/ajh.25306.
    PubMed     Text format     Abstract available


  15. ESTEY EH
    Acute myeloid leukemia: 2019 update on risk-stratification and management.
    Am J Hematol. 2018;93:1267-1291.
    PubMed     Text format     Abstract available


    September 2018
  16. BEGNA KH, Ali W, Gangat N, Elliott MA, et al
    A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status.
    Am J Hematol. 2018 Sep 19. doi: 10.1002/ajh.25290.
    PubMed     Text format    


  17. CHRISTOPEIT M, Labopin M, Gorin NC, Saraceni F, et al
    Allogeneic Stem Cell Transplantation following Relapse post Autologous Stem Cell Transplantation in adult patients with Acute Myeloid Leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
    Am J Hematol. 2018 Sep 14. doi: 10.1002/ajh.25285.
    PubMed     Text format     Abstract available


  18. JACOBY E, Bielorai B, Avigdor A, Itzhaki O, et al
    Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia.
    Am J Hematol. 2018 Sep 6. doi: 10.1002/ajh.25274.
    PubMed     Text format     Abstract available


    August 2018
  19. YANG MH, Wan WQ, Luo JS, Zheng MC, et al
    Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: interim results of the SCCLG-APL clinical study.
    Am J Hematol. 2018 Aug 30. doi: 10.1002/ajh.25271.
    PubMed     Text format     Abstract available


  20. JAIN P, Kanagal-Shamanna R, Konoplev SN, Zuo Z, et al
    Biclonal IGHV-4-34 variant hairy cell leukemia and CLL - successful treatment with ibrutinib and venetoclax.
    Am J Hematol. 2018 Aug 28. doi: 10.1002/ajh.25264.
    PubMed     Text format    


  21. HOW J, Vij KR, Ebadi M, DeFor TE, et al
    Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Am J Hematol. 2018 Aug 24. doi: 10.1002/ajh.25262.
    PubMed     Text format    


  22. ROBAK T, Burger JA, Tedeschi A, Barr PM, et al
    Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies.
    Am J Hematol. 2018 Aug 20. doi: 10.1002/ajh.25259.
    PubMed     Text format     Abstract available


  23. ASSI R, Gur HD, Loghavi S, Konoplev SN, et al
    P53 Protein Overexpression in De Novo Acute Myeloid Leukemia Patients with Normal Diploid Karyotype Correlates with FLT3 Internal Tandem Duplication and Worse Relapse-Free Survival.
    Am J Hematol. 2018 Aug 16. doi: 10.1002/ajh.25255.
    PubMed     Text format     Abstract available


  24. MI X, Griffin G, Lee W, Patel S, et al
    Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations.
    Am J Hematol. 2018 Aug 16. doi: 10.1002/ajh.25256.
    PubMed     Text format     Abstract available


  25. CUNNINGHAM I, Worthley D, Gastroenterologist C
    LEUKEMIA IN GI ORGANS AS CAUSE OF TREATMENT FAILURE: 378 CASES ANALYZED.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25250.
    PubMed     Text format     Abstract available


  26. HO G, Li Q, Brunson A, Jonas BA, et al
    Complications and Early Mortality in Patients with Acute Promyelocytic Leukemia treated in California.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25252.
    PubMed     Text format    


  27. POPHALI P, Horna P, Lasho TL, Finke CM, et al
    Splenectomy in patients with chronic myelomonocytic leukemia: Indications, histopathological findings and clinical outcomes in a single institutional series of 39 patients.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25246.
    PubMed     Text format     Abstract available


  28. XIA D, Hsi ED, Cin PD, Hasserjian RP, et al
    Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation.
    Am J Hematol. 2018 Aug 13. doi: 10.1002/ajh.25249.
    PubMed     Text format    


  29. O'BRIEN S, Patel M, Kahl BS, Horwitz SM, et al
    Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study.
    Am J Hematol. 2018 Aug 10. doi: 10.1002/ajh.25243.
    PubMed     Text format     Abstract available


  30. ABAZA Y, Cortes J, Ravandi F, Kadia T, et al
    Prognostic significance of hyperdiploidy in adult acute myeloid leukemia.
    Am J Hematol. 2018 Aug 3. doi: 10.1002/ajh.25240.
    PubMed     Text format     Abstract available


  31. ELLIOTT MA, Tefferi A
    Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
    Am J Hematol. 2018;93:578-587.
    PubMed     Text format     Abstract available


    July 2018
  32. SIEGEL SE, Advani A, Seibel N, Muffly L, et al
    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
    PubMed     Text format     Abstract available


  33. ROSENTHAL J, Naqvi AS, Luo M, Wertheim G, et al
    Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25235.
    PubMed     Text format     Abstract available


  34. SARACENI F, Beohou E, Labopin M, Arcese W, et al
    Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Am J Hematol. 2018 Jul 23. doi: 10.1002/ajh.25225.
    PubMed     Text format     Abstract available


  35. OHANIAN M, Garcia-Manero G, Levis M, Jabbour E, et al
    Sorafenib Combined with 5-azacytidine (AZA) in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia (AML).
    Am J Hematol. 2018 Jul 20. doi: 10.1002/ajh.25198.
    PubMed     Text format     Abstract available


  36. NORWOOD J, Pastoret C, Luycx O, Le Coz MF, et al
    Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life.
    Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25217.
    PubMed     Text format    


  37. FATHI AT, Hobbs G, Dey BR, Chen YB, et al
    Lenalidomide combined with mismatched microtransplantation for acute myeloid leukemia.
    Am J Hematol. 2018 Jul 17. doi: 10.1002/ajh.25218.
    PubMed     Text format    


  38. MORABITO F, Shanafelt TD, Gentile M, Reda G, et al
    Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases.
    Am J Hematol. 2018 Jul 9. doi: 10.1002/ajh.25206.
    PubMed     Text format    


  39. GILLEECE MH, Labopin M, Yakoub-Agha I, Volin L, et al
    Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Part
    Am J Hematol. 2018 Jul 7. doi: 10.1002/ajh.25211.
    PubMed     Text format     Abstract available


    June 2018
  40. PATNAIK MM, Tefferi A
    Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.
    Am J Hematol. 2018;93:824-840.
    PubMed     Text format     Abstract available


    May 2018
  41. CHYLA B, Daver N, Doyle K, McKeegan E, et al
    Genetic Biomarkers Of Sensitivity and Resistance to Venetoclax Monotherapy in Patients With Relapsed Acute Myeloid Leukemia.
    Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25146.
    PubMed     Text format    


  42. BACIGALUPO A, Van Lint MT, Sica S, Laurenti L, et al
    High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study.
    Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25131.
    PubMed     Text format    


    April 2018
  43. SIEGELE BJ, Nardi V
    Laboratory Testing in BCR-ABL1-like (Philadelphia-like) B-Lymphoblastic Leukemia/Lymphoma.
    Am J Hematol. 2018 Apr 26. doi: 10.1002/ajh.25126.
    PubMed     Text format     Abstract available


  44. CUI L, Li ZG, Chai YH, Yu J, et al
    Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
    Am J Hematol. 2018 Apr 20. doi: 10.1002/ajh.25124.
    PubMed     Text format     Abstract available


  45. GORIN NC, Labopin M, Blaise D, Dumas PY, et al
    Optimizing the Pretransplant Regimen for Autologous Stem Cell Transplantation in Acute Myelogenous Leukemia: Better Outcomes with Busulfan and Melphalan compared with Busulfan and Cyclophosphamide in high Risk Patients autografted in First Complete Re
    Am J Hematol. 2018 Apr 12. doi: 10.1002/ajh.25105.
    PubMed     Text format     Abstract available


  46. CAO J, Wang G, Cheng H, Wei C, et al
    Potent anti-leukemia activities of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2018 Apr 10. doi: 10.1002/ajh.25108.
    PubMed     Text format     Abstract available


  47. PUNGOLINO E, Rossi G, De Canal G, Trojani A, et al
    Nilotinib induced Bone Marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia.
    Am J Hematol. 2018 Apr 10. doi: 10.1002/ajh.25106.
    PubMed     Text format    


  48. CAOCCI G, Mulas O, Annunziata M, Luciano L, et al
    Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.
    Am J Hematol. 2018 Apr 6. doi: 10.1002/ajh.25102.
    PubMed     Text format    


    March 2018
  49. JIN CH, Li Y, Xia J, Li Y, et al
    CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion.
    Am J Hematol. 2018 Mar 30. doi: 10.1002/ajh.25099.
    PubMed     Text format     Abstract available


  50. CZYZ A, Labopin M, Giebel S, Socie G, et al
    Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Soc
    Am J Hematol. 2018 Mar 25. doi: 10.1002/ajh.25091.
    PubMed     Text format     Abstract available


  51. LI Z, Labopin M, Ciceri F, Blaise D, et al
    Haploidentical transplantation outcomes for secondary acute myeloid leukemia: ALWP of the EBMT study.
    Am J Hematol. 2018 Mar 14. doi: 10.1002/ajh.25087.
    PubMed     Text format     Abstract available


  52. OGDEN J, Yui J, Ali W, Mudireddy M, et al
    Pre-Anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia.
    Am J Hematol. 2018 Mar 6. doi: 10.1002/ajh.25083.
    PubMed     Text format    


  53. CANAANI J, Labopin M, Huang XJ, Arcese W, et al
    T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia. A report from the Acute Leukemia Working Party of the EBMT.
    Am J Hematol. 2018 Mar 2. doi: 10.1002/ajh.25082.
    PubMed     Text format     Abstract available


  54. JABBOUR E, Kantarjian H
    Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
    Am J Hematol. 2018;93:442-459.
    PubMed     Text format     Abstract available


    February 2018
  55. KHODER A, Al Obaidi M, Babb A, Liu C, et al
    Chronic neutrophilic leukemia.
    Am J Hematol. 2018 Feb 23. doi: 10.1002/ajh.25073.
    PubMed     Text format    


  56. WIERZBOWSKA A, Wawrzyniak E, Pluta A, Robak T, et al
    Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial.
    Am J Hematol. 2018 Feb 8. doi: 10.1002/ajh.25062.
    PubMed     Text format    


  57. OTTONE T, Alfonso V, Iaccarino L, Hasan SK, et al
    Longitudinal detection of DNMT3A(R882H) transcripts in patients with acute myeloid leukemia.
    Am J Hematol. 2018 Feb 8. doi: 10.1002/ajh.25061.
    PubMed     Text format    


  58. BORLENGHI E, Pagani C, Zappasodi P, Bernardi M, et al
    Secondary acute myeloid leukaemia in elderly patients: Patient's fitness criteria and ELN prognostic stratification can be applied to guide treatment decisions. An analysis of 280 patients by the network rete ematologica lombarda (REL).
    Am J Hematol. 2018;93:E54-E57.
    PubMed     Text format    


  59. GENTILE M, Shanafelt TD, Mauro FR, Laurenti L, et al
    Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.
    Am J Hematol. 2018;93:E35-E37.
    PubMed     Text format    


    January 2018
  60. HERGOTT CB, Pozdnyakova O
    Evans syndrome secondary to undiagnosed chronic lymphocytic leukemia in a patient with unexplained bleeding.
    Am J Hematol. 2018 Jan 17. doi: 10.1002/ajh.25039.
    PubMed     Text format    


  61. CASSADAY RD, Stevenson PA, Wood BL, Becker PS, et al
    Description and Prognostic Significance of the Kinetics of Minimal Residual Disease Status in Adults with Acute Lymphoblastic Leukemia Treated with HyperCVAD.
    Am J Hematol. 2018 Jan 10. doi: 10.1002/ajh.25030.
    PubMed     Text format     Abstract available


  62. ARAI Y, Kondo T, Shigematsu A, Tanaka J, et al
    Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults.
    Am J Hematol. 2018;93:47-57.
    PubMed     Text format     Abstract available


  63. BARRETT A, Catherwood M, Thornton P, Murphy P, et al
    Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy.
    Am J Hematol. 2018;93:E16-E17.
    PubMed     Text format    


  64. GUILLERMIN Y, Herbaux C, Subtil F, Aurran-Schleinitz T, et al
    Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO group.
    Am J Hematol. 2018;93:E24-E27.
    PubMed     Text format    


  65. CALDWELL I, Ruskova A, Eaddy N, Bain BJ, et al
    Acute leukemic transformation of myelodysplastic syndrome: Is cytochemistry still relevant?
    Am J Hematol. 2018;93:148-149.
    PubMed     Text format    


    December 2017
  66. ASSI R, Ravandi F
    FLT3 Inhibitors in Acute Myeloid Leukemia: Choosing the Best when the Optimal Does Not Exist.
    Am J Hematol. 2017 Dec 29. doi: 10.1002/ajh.25027.
    PubMed     Text format     Abstract available


  67. DECROOCQ J, Itzykson R, Vigouroux S, Michallet M, et al
    Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Societe Francophone de Greffe de Moelle et de Therapie Cel
    Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25004.
    PubMed     Text format     Abstract available


  68. BAIN BJ
    Pure erythroid leukemia.
    Am J Hematol. 2017 Dec 11. doi: 10.1002/ajh.25005.
    PubMed     Text format    


  69. DINARDO CD, Rausch CR, Benton C, Kadia T, et al
    Clinical Experience with the BCL2-inhibitor Venetoclax in Combination Therapy for Relapsed and Refractory Acute Myeloid Leukemia and Related Myeloid Malignancies.
    Am J Hematol. 2017 Dec 8. doi: 10.1002/ajh.25000.
    PubMed     Text format     Abstract available


  70. TROUSSARD X, Cornet E
    Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2017;92:1382-1390.
    PubMed     Text format     Abstract available


  71. CHAPIRO E, Lesty C, Gabillaud C, Durot E, et al
    "Double-hit" chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain.
    Am J Hematol. 2017 Dec 1. doi: 10.1002/ajh.24990.
    PubMed     Text format     Abstract available


  72. MOLICA M, Canichella M, Alunni Fegatelli D, Colafigli G, et al
    The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.
    Am J Hematol. 2017;92:E661-E664.
    PubMed     Text format    


  73. KOBAYASHI T, Nannya Y, Ichikawa M, Oritani K, et al
    A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study).
    Am J Hematol. 2017;92:1324-1332.
    PubMed     Text format     Abstract available


    November 2017
  74. JABBOUR E, Dull J, Yilmaz M, Khoury JD, et al
    Outcome of Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia after Blinatumomab Failure: No Change in the Level of CD19 Expression.
    Am J Hematol. 2017 Nov 27. doi: 10.1002/ajh.24987.
    PubMed     Text format     Abstract available


  75. GODET S, Protin C, Dupuis J, Dartigeas C, et al
    Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24981.
    PubMed     Text format    


  76. WALTER RB, Michaelis LC, Othus M, Uy GL, et al
    Intergroup LEAP Trial (S1612): A Randomized Phase 2/3 Platform Trial to Test Novel Therapeutics in Medically Less Fit Older Adults with Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 22. doi: 10.1002/ajh.24980.
    PubMed     Text format    


  77. VENTON G, Courtier F, Charbonnier A, D'Incan E, et al
    Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
    Am J Hematol. 2017 Nov 17. doi: 10.1002/ajh.24973.
    PubMed     Text format     Abstract available


  78. ALTMAN JK, Foran JM, Pratz KW, Trone D, et al
    Phase 1 Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 15. doi: 10.1002/ajh.24974.
    PubMed     Text format     Abstract available


  79. DEANGELO DJ, Brunner AM, Werner L, Avigan D, et al
    A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myeloid Leukemia.
    Am J Hematol. 2017 Nov 9. doi: 10.1002/ajh.24968.
    PubMed     Text format     Abstract available


  80. CANAANI J, Savani BN, Labopin M, Huang XJ, et al
    Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation.
    Am J Hematol. 2017 Nov 8. doi: 10.1002/ajh.24963.
    PubMed     Text format     Abstract available


  81. SANDMAIER BM, Khaled S, Oran B, Gammon G, et al
    Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Remission Following Allogeneic Hematopoietic Stem Cell Transplant.
    Am J Hematol. 2017 Nov 1. doi: 10.1002/ajh.24959.
    PubMed     Text format     Abstract available


    October 2017
  82. MINETTO P, Guolo F, Clavio M, Kunkl A, et al
    A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis.
    Am J Hematol. 2017 Oct 28. doi: 10.1002/ajh.24956.
    PubMed     Text format    


  83. COOMBS CC, Mathews SP
    Acute promyelocytic leukemia and chronic lymphocytic leukemia diagnosed concurrently.
    Am J Hematol. 2017 Oct 20. doi: 10.1002/ajh.24950.
    PubMed     Text format    


  84. ABAZA Y, Kantarjian HM, Faderl S, Jabbour E, et al
    Hyper-CVAD plus Nelarabine in Newly Diagnosed Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma.
    Am J Hematol. 2017 Oct 19. doi: 10.1002/ajh.24947.
    PubMed     Text format     Abstract available


  85. ALHURAIJI A, Kantarjian H, Boddu P, Ravandi F, et al
    Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24943.
    PubMed     Text format     Abstract available


  86. KHODER A, Al Obaidi M, Wiles N, Nadal-Melsio E, et al
    Lymphoplasmacytoid cytology in plasma cell leukemia.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24940.
    PubMed     Text format    


  87. TEFFERI A, Hanson CA, Ketterling RP
    Revisiting the need for bone marrow examination in chronic myeloid leukemia.
    Am J Hematol. 2017 Oct 13. doi: 10.1002/ajh.24942.
    PubMed     Text format    


  88. PATNAIK MM, Vallapureddy R, Yalniz FF, Hanson CA, et al
    Therapy Related-Chronic Myelomonocytic Leukemia (CMML): Molecular, Cytogenetic and Clinical Distinctions from de novo CMML.
    Am J Hematol. 2017 Oct 11. doi: 10.1002/ajh.24939.
    PubMed     Text format     Abstract available


  89. IZZI V, Lakkala J, Devarajan R, Savolainen ER, et al
    Vanin 1 (VNN1) levels predict poor outcome in acute myeloid leukemia.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24925.
    PubMed     Text format    


  90. LAZAREVIC VL, Labopin M, Wu D, Yakoub-Agha I, et al
    Relatively favourable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24928.
    PubMed     Text format     Abstract available


  91. EL FAKIH R, Jabbour E, Ravandi F, Hassanein M, et al
    Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.
    Am J Hematol. 2017 Oct 3. doi: 10.1002/ajh.24926.
    PubMed     Text format     Abstract available


  92. SPERR WR, Herndlhofer S, Gleixner K, Girschikofsky M, et al
    Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >/=60 years.
    Am J Hematol. 2017;92:E567-E574.
    PubMed     Text format     Abstract available


  93. RASHIDI A, Linden MA, DeFor TE, Warlick E, et al
    History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Am J Hematol. 2017;92:1032-1036.
    PubMed     Text format     Abstract available


  94. SHIMONI A, Vago L, Bernardi M, Yerushalmi R, et al
    Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
    Am J Hematol. 2017;92:1011-1019.
    PubMed     Text format     Abstract available


  95. MOLOGNI L, Piazza R, Khandelwal P, Pirola A, et al
    Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.
    Am J Hematol. 2017;92:E623-E625.
    PubMed     Text format    


  96. JAIN P, Burger JA, Khoury JD
    CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lympho-proliferation.
    Am J Hematol. 2017;92:1113-1114.
    PubMed     Text format    


    September 2017
  97. GAKSCH L, Kashofer K, Heitzer E, Quehenberger F, et al
    Residual disease detection using targeted parallel sequencing predicts relapse in cytogenetically normal acute myeloid leukemia.
    Am J Hematol. 2017 Sep 29. doi: 10.1002/ajh.24922.
    PubMed     Text format     Abstract available


  98. BRECCIA M, Colafigli G, Molica M, Scalzulli E, et al
    Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
    Am J Hematol. 2017 Sep 28. doi: 10.1002/ajh.24916.
    PubMed     Text format    


  99. HAMPEL PJ, Chaffee KG, King RL, Simonetto D, et al
    Liver Dysfunction in Chronic Lymphocytic Leukemia: Prevalence, Outcomes, and Pathological Findings.
    Am J Hematol. 2017 Sep 22. doi: 10.1002/ajh.24915.
    PubMed     Text format     Abstract available


  100. CHANG YJ, Zhao XS, Wang Y, Liu YR, et al
    Effects of Pre- and Post-transplantation Minimal Residual Disease on Outcomes in Pediatric Patients with Acute Myeloid Leukemia Receiving Human Leukocyte Antigen-matched or Mismatched Related Donor Allografts.
    Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24910.
    PubMed     Text format    


  101. GORIN NC, Labopin M, Pabst T, Remenyi P, et al
    Unrelated matched versus autologous transplantation in adult patients with good and intermediate risk acute myelogenous leukemia in first molecular remission.
    Am J Hematol. 2017 Sep 11. doi: 10.1002/ajh.24904.
    PubMed     Text format     Abstract available


  102. HALLEK M
    Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Am J Hematol. 2017;92:946-965.
    PubMed     Text format     Abstract available


  103. PERERA LP, Zhang M, Nakagawa M, Petrus MN, et al
    Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
    Am J Hematol. 2017;92:892-901.
    PubMed     Text format     Abstract available


  104. BEHRENS M, Chowdry RP, Saba S, Saba NS, et al
    A centrocyte blood count of a quarter million.
    Am J Hematol. 2017;92:972-973.
    PubMed     Text format    


    August 2017
  105. SHI CR, Nambudiri VE
    Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
    Am J Hematol. 2017 Aug 24. doi: 10.1002/ajh.24894.
    PubMed     Text format    


  106. GOLDBERG SL, Cortes J, Gambacorti-Passerini C, Hehlmann R, et al
    First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.
    Am J Hematol. 2017 Aug 17. doi: 10.1002/ajh.24887.
    PubMed     Text format     Abstract available


  107. COLTRO G, Mannelli F, Guglielmelli P, Pacilli A, et al
    A life-threatening ruxolitinib discontinuation syndrome.
    Am J Hematol. 2017;92:833-838.
    PubMed     Text format    


  108. YSEBAERT L, Aurran-Schleinitz T, Dartigeas C, Dilhuydy MS, et al
    Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
    Am J Hematol. 2017;92:E166-E168.
    PubMed     Text format    


    July 2017
  109. BEGNA K, Al-Kali A, Elliott M, Foran J, et al
    Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
    Am J Hematol. 2017 Jul 21. doi: 10.1002/ajh.24866.
    PubMed     Text format    


  110. BAIN BJ
    Pure erythroid leukemia: the need gather data on this condition as defined in the World Health Organisation classification.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24863.
    PubMed     Text format    


  111. VALLAPUREDDY R, Lasho TL, Hoversten K, Finke CM, et al
    Nucleophosmin 1 (NPM1) Mutations in Chronic Myelomonocytic Leukemia and Their Prognostic Relevance.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24861.
    PubMed     Text format    


  112. WANG W, Wang S, Medeiros LJ, Khoury JD, et al
    Response to Dr. Bain's comment on our review article: Pure Erythroid Leukemia.
    Am J Hematol. 2017 Jul 13. doi: 10.1002/ajh.24862.
    PubMed     Text format    


  113. JAROSOVA M, Hruba M, Oltova A, Plevova K, et al
    Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients.
    Am J Hematol. 2017 Jul 11. doi: 10.1002/ajh.24852.
    PubMed     Text format    


  114. KLIL-DRORI AJ, Yin H, Azoulay L, Harnois M, et al
    Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
    Am J Hematol. 2017 Jul 3. doi: 10.1002/ajh.24838.
    PubMed     Text format    


  115. RHEE SJ, Lee JW, Yu KS, Hong KT, et al
    Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Am J Hematol. 2017;92:607-613.
    PubMed     Text format     Abstract available


    June 2017
  116. JAIN P, Kantarjian H, Jain N, Short NJ, et al
    Clinical characteristics and outcomes of previously untreated patients with adult onset T-ALL and T-lymphoblastic lymphoma (T-LL) with Hyper-CVAD based regimens.
    Am J Hematol. 2017 Jun 24. doi: 10.1002/ajh.24833.
    PubMed     Text format    


  117. LEVIN A, Kleman A, Rein L, Tarima S, et al
    Early Mortality in Patients with Acute Myelogenous Leukemia Treated in Teaching versus Non-teaching Hospitals: A Large Database Analysis.
    Am J Hematol. 2017 Jun 20. doi: 10.1002/ajh.24825.
    PubMed     Text format    


  118. EDER S, Canaani J, Beohou E, Labopin M, et al
    Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Socie
    Am J Hematol. 2017 Jun 14. doi: 10.1002/ajh.24823.
    PubMed     Text format     Abstract available


  119. TERRY CM, Shallis RM, Estey E, Lim SH, et al
    Day 14 bone marrow examination in the management of acute myeloid leukemia.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24818.
    PubMed     Text format     Abstract available


  120. BAZIN J, Karnik L, Tudor-Williams G, Kelly AM, et al
    Juvenile myelomonocytic leukemia in an infant with congenital HIV and CMV infection.
    Am J Hematol. 2017 Jun 13. doi: 10.1002/ajh.24815.
    PubMed     Text format    


  121. CROMBIE J, Davids MS
    IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2017 Jun 7. doi: 10.1002/ajh.24808.
    PubMed     Text format     Abstract available


  122. SALEM A, Loghavi S, Tang G, Huh YO, et al
    Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
    Am J Hematol. 2017;92:520-528.
    PubMed     Text format     Abstract available


  123. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase.
    Am J Hematol. 2017;92:E91-E93.
    PubMed     Text format    


  124. DE ROCCO D, Melazzini F, Marconi C, Pecci A, et al
    Mutations of RUNX1 in families with inherited thrombocytopenia.
    Am J Hematol. 2017;92:E86-E88.
    PubMed     Text format    


    May 2017
  125. RASHIDI A, Ali AM, Vij KR, Shanley R, et al
    Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
    Am J Hematol. 2017 May 31. doi: 10.1002/ajh.24804.
    PubMed     Text format    


  126. JABBOUR E, Daver NG, Short NJ, Huang X, et al
    Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia.
    Am J Hematol. 2017 May 27. doi: 10.1002/ajh.24799.
    PubMed     Text format     Abstract available


  127. KONDO T, Nagamura-Inoue T, Tojo A, Nagamura F, et al
    Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia.
    Am J Hematol. 2017 May 20. doi: 10.1002/ajh.24793.
    PubMed     Text format     Abstract available


  128. ALDOSS I, Song J, Stiller T, Nguyen T, et al
    Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24783.
    PubMed     Text format     Abstract available


  129. RAGON BK, Daver N, Garcia-Manero G, Ravandi F, et al
    Minimal Residual Disease Eradication with Epigenetic Therapy in Core Binding Factor Acute Myeloid Leukemia.
    Am J Hematol. 2017 May 11. doi: 10.1002/ajh.24782.
    PubMed     Text format     Abstract available


  130. GONCALVES MV, Rodrigues CA, Metze IGHL, Lacerda MP, et al
    Chronic lymphocytic leukemia in Brazil: A retrospective analysis of 1903 cases.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24779.
    PubMed     Text format    


  131. NANAH R, McCullough K, Hogan W, Begna K, et al
    Outcome of Elderly Patients after Failure to Hypomethylating Agents Given as Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience.
    Am J Hematol. 2017 May 5. doi: 10.1002/ajh.24780.
    PubMed     Text format     Abstract available


  132. CASTAGNETTI F, Gugliotta G, Breccia M, Iurlo A, et al
    The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Am J Hematol. 2017 May 2. doi: 10.1002/ajh.24774.
    PubMed     Text format     Abstract available



  133. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
    Am J Hematol. 2017;92:E85.
    PubMed     Text format    


    April 2017
  134. CANAANI J, Savani BN, Labopin M, Michallet M, et al
    ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia - a report from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Apr 25. doi: 10.1002/ajh.24771.
    PubMed     Text format     Abstract available


  135. BHATT VR, Shostrom V, Giri S, Gundabolu K, et al
    Early Mortality and Overall Survival of Acute Myeloid Leukemia Based on Facility Type.
    Am J Hematol. 2017 Apr 24. doi: 10.1002/ajh.24767.
    PubMed     Text format     Abstract available


  136. LARSEN JT, Shanafelt TD, Leis JF, LaPlant B, et al
    Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study.
    Am J Hematol. 2017 Apr 12. doi: 10.1002/ajh.24762.
    PubMed     Text format     Abstract available


  137. BAPTISTA MJ, Granada I, Morgades M, Calasanz MJ, et al
    Monosomal karyotype in chronic lymphocytic leukemia: association with clinical and biological features and potential prognostic significance.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24754.
    PubMed     Text format    


  138. REDA G, Cassin R, Fattizzo B, Giannarelli D, et al
    Chronic lymphocytic leukemia (CLL) and prognostic models: A bridge between clinical and biological markers.
    Am J Hematol. 2017 Apr 6. doi: 10.1002/ajh.24755.
    PubMed     Text format    


  139. SACHA T, Gora-Tybor J, Szarejko M, Bober G, et al
    A multicenter prospective study on efficacy and safety of imatinib generics; a report from Polish Adult Leukemia Group imatinib generics registry.
    Am J Hematol. 2017 Apr 4. doi: 10.1002/ajh.24748.
    PubMed     Text format     Abstract available


  140. YU Y, Zhang T, Wang Q, Wu D, et al
    Counting bone marrow blasts as a percentage of nonerythroid cells improves the prognostic evaluation of MDS with erythroid predominance.
    Am J Hematol. 2017;92:E55-E57.
    PubMed     Text format    


  141. PEMMARAJU N, Jain P, Medeiros LJ, Jorgenson JL, et al
    PET-positive lymphadenopathy in CLL-Not always Richter transformation.
    Am J Hematol. 2017;92:405-406.
    PubMed     Text format    


    March 2017
  142. WEINBERG OK, Gibson CJ, Blonquist TM, Neuberg D, et al
    NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO Classification.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24739.
    PubMed     Text format    


  143. CANAANI J, Labopin M, Socie G, Nihtinen A, et al
    Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24737.
    PubMed     Text format     Abstract available


  144. KANTARJIAN HM, Schuster MW, Jain N, Advani A, et al
    A Phase 1 Study of AMG 900, an Orally Administered Pan-Aurora Kinase Inhibitor, in Adult Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24736.
    PubMed     Text format     Abstract available


  145. ALFONSO A, Montalban-Bravo G, Takahashi K, Jabbour EJ, et al
    Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.
    Am J Hematol. 2017 Mar 28. doi: 10.1002/ajh.24735.
    PubMed     Text format     Abstract available


  146. KANDARPA M, Wu YM, Robinson D, Burke PW, et al
    Clinical Characteristics and Whole Exome/Transcriptome Sequencing of Coexisting Chronic Myeloid Leukemia and Myelofibrosis.
    Am J Hematol. 2017 Mar 23. doi: 10.1002/ajh.24728.
    PubMed     Text format     Abstract available


  147. GRIFFIN PT, Komrokji RS, Sweet K, Al Ali NH, et al
    Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
    Am J Hematol. 2017;92:232-237.
    PubMed     Text format     Abstract available


    February 2017
  148. NAKASONE H, Fuji S, Yakushijin K, Onizuka M, et al
    Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation.
    Am J Hematol. 2017;92:171-178.
    PubMed     Text format     Abstract available


  149. DINARDO CD, Luskin MR, Carroll M, Smith C, et al
    Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.
    Am J Hematol. 2017;92:E14-E15.
    PubMed     Text format    


    January 2017
  150. TEFFERI A, Barbui T
    Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2017;92:94-108.
    PubMed     Text format     Abstract available


  151. RAGON BK, Kantarjian H, Jabbour E, Ravandi F, et al
    Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
    Am J Hematol. 2017;92:7-11.
    PubMed     Text format     Abstract available


  152. JAIN P, Kantarjian H, Jabbour E, Kanagal-Shamanna R, et al
    Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
    Am J Hematol. 2017;92:E3-E4.
    PubMed     Text format    


  153. JAIN P, Nagarajan P, Prayag P, Benton CB, et al
    Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML.
    Am J Hematol. 2017;92:119-120.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: